By Devika Patel
Knoxville, Tenn., Aug. 5 - Alexza Pharmaceuticals, Inc. arranged an $18.05 million registered direct offering of units, according to a prospectus supplement filed Thursday with the Securities and Exchange Commission.
The company will sell 6,685,183 units of one common share and a half-share warrant at $2.70 apiece.
The whole warrants are exercisable at $3.30 for five years. The strike price represents a 10% premium to the Aug. 4 closing share price of $3.00.
RBC Capital Markets Corp. is the agent. JMP Securities LLC is co-agent.
Settlement is expected Aug. 10.
Proceeds will be used for general corporate purposes, including clinical trial, research and development, general and administrative and manufacturing expenses.
Alexza is a Palo Alto, Calif., pharmaceutical company.
| Issuer: | Alexza Pharmaceuticals, Inc.
|
| Issue: | Units of one common share and a half-share warrant
|
| Amount: | $18,049,994
|
| Units: | 6,685,183
|
| Price: | $2.70
|
| Warrants: | One half-share warrant per unit
|
| Warrant expiration: | Five years
|
| Warrant strike price: | $3.30
|
| Agents: | RBC Capital Markets Corp., JMP Securities LLC
|
| Pricing date: | Aug. 5
|
| Settlement date: | Aug. 10
|
| Stock symbol: | Nasdaq: ALXA
|
| Stock price: | $3.00 at close Aug. 4
|
| Market capitalization: | $132.31 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
